Elixir Pharmaceuticals, Inc.: Series D $12M

Posted in I - Series D, Q - 2Q09, R - NORTH EAST, X - Diabetes, X - Metabolism, X - Obesity, XX - MA

Elixir Pharmaceuticals (Cambridge, MA) a late-stage pharmaceutical company focused on the treatment of metabolic diseases such as diabetes and obesity, closed a $12M Series D financing. Participants include MPM Capital, Arch Venture Partners, Oxford Bioscience Partners, Omega Funds and Physic Ventures.

Jan

2009

7TM Pharma, A/S: Series E $15M

Posted in I - Series E, Q - 1Q09, R - INTERNATIONAL, X - Cardiology, X - Metabolism, X - Obesity

7TM Pharma (Denmark) a clinical-stage company focused on discovery and development of therapeutics for metabolic diseases including obesity and cardiovascular diseases, closed a $15M Series E financing. Participants include Novo, Alta Partners, LD Pensions, Index Ventures, Johnson & Johnson Development Corp, Sofinnova Capital, Lombard Odier Darier Hentsch & Cie, SR One, Global Life Science Ventures, [...]

Feb

2008

Escoublac, Inc.: Series A $6.7M

Posted in I - Series A, Q - 1Q08, R - NORTH EAST, X - Diabetes, X - Metabolism, X - Obesity

Escoublac (Cambridge, MA) the first occupant in Biogen Idec new Innovation Incubator is developing treatments for metabolic diseases, type II diabetes and obesity, closed a $6.7M Series A financing. Participants include Biogen Idec.

Feb

2008

Gelesis, Inc.: Series A $16.0M

Posted in I - Series A, Q - 1Q08, R - NORTH EAST, X - GI, X - Obesity

Gelsis (Boston, MA) is developing a breakthrough treatment for obesity and other gastrointestinal disorders has closed a $16M Series A. Participants include OrbiMed, Queensland BioCapital Funds, PureTech Ventures, Lansing Brown Investments and the Cape Family Fund.

to top of page...